Oxbryta (voxelotor tablets, tablets for oral suspension – Global Blood Therapeutics/Pfizer) — Cigna

Initial criteria

• Coverage of Oxbryta is not approved due to market withdrawal; considered experimental, investigational, or unproven for all uses.